CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Long-term dual antiplatelet-induced intestinal injury resulting in translocation of intestinal bacteria into blood circulation increased the incidence of adverse events after PCI in patients with coronary artery disease Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease : A Special Report From the American Heart Association and American College of Cardiology MINOCA: a heterogenous group of conditions associated with myocardial damage International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey Abnormalities in 3-Dimensional Left Ventricular Mechanics With Anthracycline Chemotherapy Are Associated With Systolic and Diastolic Dysfunction Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI

Consensus2019 Oct 15;74(15):1966-2011.

JOURNAL:J Am Coll Cardiol. Article Link

2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee

Hollenberg SM, Warner Stevenson L, Ahmad T Keywords: ACC Expert Consensus Decision Pathway; CHF; angiotensin receptor-neprilysin inhibitors; beta blockers; comorbidities; diuretics; guideline-directed medical therapy; heart failure

FULL TEXT PDF